Xbrane Biopharma AB
http://xbrane.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Xbrane Biopharma AB
Xbrane Pulls In US Ranibizumab Partner After FDA Disappointment
Xbrane Biopharma’s recent CRL for its proposed US biosimilar to Lucentis has not prevented the Swedish company from announcing a successor to Bausch + Lomb to partner on the biosimilar’s US marketing and commercialization.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
Stada Set To Minimize Xbrane Ownership As Swedish Firm Hunts For Cash
“We are extremely well aware of the consequences for investors that cannot protect their ownership share in this transaction,” Xbrane has told its investors, as the Swedish firm looks to tie up much-needed capital injection via a right issue to fuel its pipeline of biosimilar projects.
Who’s Hired? Rosemont Drives M&A With New Appointments
UK liquids specialist Rosemont Pharmaceuticals has appointed a new chief corporate development officer to drive M&A. Meanwhile, EuroAPI has named a chief transformation officer, Zentiva’s CEO has joined Medicines for Europe’s executive committee, Hikma has changed company secretary, and Xbrane has made alterations to its nominations committee.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Primm Pharma Srl
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice